Børge Sørvoll
Director of Finance/CFO at ARCTICZYMES TECHNOLOGIES ASA
Net worth: 223 185 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Marit Sjo Lorentzen | M | 56 |
Biotec BetaGlucans AS
 Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The private company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | - |
| Olav Lanes | M | 52 | 24 years | |
| Jethro Holter | M | 52 |
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The private company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | 9 years |
| Dino DiCamillo | M | 66 | 12 years | |
| Rolf Einar Engstad | M | 65 |
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The private company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | - |
| Dirk Hahneiser | M | 56 | 2 years | |
| Bernd Striberny | M | - | - | |
| Darren Ellis | M | - | 2 years | |
| Michael Akoh | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Svein Wilhelm Faye Lien | M | 70 | 7 years | |
| Martin Hunt | M | 66 | - | |
| Volker Wedershoven | M | - | - | |
| Kjersti Grimsrud | F | 63 | 4 years | |
| Marie Roskrow | M | - | - | |
| Richard Stuart Godfrey | M | 58 | - | |
| Arne Reinemo | M | - | - | |
| Inger Rydin | F | 67 | 5 years | |
| Christian Jørgensen | M | 65 | 2 years | |
| Jane Theaker | F | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Norway | 19 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Børge Sørvoll
- Personal Network
